Tom 16, Nr 1 (2019)
Farmakoterapia chorób układu krążenia
Opublikowany online: 2019-03-28

dostęp otwarty

Wyświetlenia strony 1307
Wyświetlenia/pobrania artykułu 1132
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Riwaroksaban — nowy lek plejotropowy o szerokim spektrum działań

Anna E. Płatek1, Filip M. Szymański1
Choroby Serca i Naczyń 2019;16(1):34-40.

Streszczenie

Doustne antykoagulanty niebędące antagonistami witaminy K (NOAC) są lekami, które stosunkowo niedawno wprowadzono do praktyki klinicznej, ale okazały się niezwykle skuteczne i bardzo chętnie oraz szeroko stosowane. Doskonale znana jest skuteczność NOAC, w tym riwaroksabanu, w zapobieganiu udarowi mózgu oraz incydentom zakrzepowo-zatorowym w grupach pacjentów z wielorakimi wskazaniami do leczenia przeciwzakrzepowego. Riwaroksaban wykazuje nie tylko pożądany wpływ na procesy zakrzepowo-zatorowe, ale prawdopodobnie powoduje również wiele działań plejotropowych, które łączą się z ograniczeniem uszkodzenia naczyń krwionośnych związanym z występowaniem czynników ryzyka sercowo-naczyniowego, oraz wykazuje potencjał hamowania rozwoju zmian miażdżycowych. W poniższym opracowaniu przedstawiono najnowszą wiedzę dotyczącą nowych potencjalnych wskazań do stosowania tego leku.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15(5): 625–651.
  2. Heidbuchel H, Verhamme P, Alings M, et al. ESC Scientific Document Group. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
  3. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
  4. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3(3): 514–521.
  5. Bayer Pharma AG. Xarelto (rivaroxaban) 2.5 mg film-coated tablets: EU summary of product characteristics. Bayer Pharma AG, Berlin 2013.
  6. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010; 70(16): 2153–2170.
  7. Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators, ROCKET AF Investigators, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  8. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014; 124(6): 955–962.
  9. Camm AJ, Amarenco P, Haas S, et al. XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37(14): 1145–1153.
  10. Ross R, Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999; 340(2): 115–126.
  11. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917): 868–874.
  12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685–1695.
  13. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341(8): 586–592.
  14. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004; 109(22): 2698–2704.
  15. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005; 131(4): 417–430.
  16. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008; 14(10): 429–440.
  17. Borissoff JI, Spronk HMH, Heeneman S, et al. Is thrombin a key player in the ‘coagulation-atherogenesis’ maze? Cardiovasc Res. 2009; 82(3): 392–403.
  18. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801): 258–264.
  19. Wang D, Paria BC, Zhang Q, et al. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injury-induced restenosis. Circ Res. 2009; 104(9): 1066–1075.
  20. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007; 27(1): 27–36.
  21. Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011; 364(18): 1746–1760.
  22. Ragosta M, Gimple LW, Gertz SD, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1994; 89(3): 1262–1271.
  23. Ellinghaus P, Laux V, Perzborn E. Effect of rivaroxaban on thrombin-induced pro-inflammatory gene expression in human umbilical vein endothelial cells. J Thromb Haemost. 2011(9): 491.
  24. Ringwala SM, Dibattiste PM, Schneider DJ. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis. 2012; 34(3): 291–296.
  25. Zhou Q, Bea F, Preusch M, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011; 2011: 432080.
  26. Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015; 242(2): 639–646.
  27. Wu TC, Chan JS, Lee CY, et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015; 14: 81.
  28. Goto M, Miura SI, Suematsu Y, et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol. 2016; 220: 602–607.
  29. Imano H, Kato R, Tanikawa S, et al. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. J Pharmacol Sci. 2018; 137(3): 274–282.
  30. Perzborn E, Heitmeier S, Laux V. Effects of r varoxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015; 20(6): 554–562.
  31. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9–19.
  32. Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators, COMPASS investigators, COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377(14): 1319–1330.
  33. Namba S, Yamaoka-Tojo M, Kakizaki R, et al. Erratum to: Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017; 32(8): 983.
  34. Kim JB, Joung HJ, Lee JM, et al. Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial. Trials. 2016; 17(1): 422.